252 related articles for article (PubMed ID: 8894526)
1. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
Wiseman LR; Goa KL
Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
[TBL] [Abstract][Full Text] [Related]
2. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
Wiseman LR; McTavish D
Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
[TBL] [Abstract][Full Text] [Related]
4. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
[TBL] [Abstract][Full Text] [Related]
5. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Clemett D; Lamb HM
Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
[TBL] [Abstract][Full Text] [Related]
6. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
[TBL] [Abstract][Full Text] [Related]
7. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
Michaud LB; Buzdar AU
Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced breast cancer with formestane.
Murray R; Pitt P
Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
[TBL] [Abstract][Full Text] [Related]
9. Letrozole: a review of its use in postmenopausal women with breast cancer.
Simpson D; Curran MP; Perry CM
Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
[TBL] [Abstract][Full Text] [Related]
10. Formestane in the treatment of advanced postmenopausal breast cancer.
Possinger K; Jonat W; Höffken K
Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E
Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217
[TBL] [Abstract][Full Text] [Related]
12. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
[TBL] [Abstract][Full Text] [Related]
13. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.
Vorobiof DA; Kleeberg UR; Perez-Carrion R; Dodwell DJ; Robertson JF; Calvo L; Dowsett M; Clack G
Ann Oncol; 1999 Oct; 10(10):1219-25. PubMed ID: 10586340
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane.
Dowsett M
Ann Oncol; 1994; 5 Suppl 7():S3-5. PubMed ID: 7873460
[TBL] [Abstract][Full Text] [Related]
15. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
[TBL] [Abstract][Full Text] [Related]
16. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
Harper-Wynne C; Coombes RC
Eur J Cancer; 1999 May; 35(5):744-6. PubMed ID: 10505035
[TBL] [Abstract][Full Text] [Related]
17. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Wiseman LR; Adkins JC
Drugs Aging; 1998 Oct; 13(4):321-32. PubMed ID: 9805213
[TBL] [Abstract][Full Text] [Related]
18. Severe immune thrombocytopenia during formestane treatment.
Español I; Muñíz-Díaz E; Alonso MC; Pujol-Moix N
Haematologica; 1998 Oct; 83(10):953-4. PubMed ID: 9830809
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of formestane in postmenopausal women with breast cancer.
Joseph JK; Lim AK
Med J Malaysia; 1998 Mar; 53(1):37-41. PubMed ID: 10968135
[TBL] [Abstract][Full Text] [Related]
20. Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
Lamb HM; Adkins JC
Drugs; 1998 Dec; 56(6):1125-40. PubMed ID: 9878997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
